Possibilities of combined antiplatelet and anticoagulant therapy in older patients without atrial fibrillation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a clinical observation of an elderly patient who underwent total arthroplasty of the left hip joint after a fracture of the femoral neck. The possibilities of the selection of antiplatelet therapy taking into account the cardiovascular risk, concomitant pathology and the patient's age are discussed.

Full Text

Restricted Access

About the authors

V. N Larina

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: larinav0mail ru
117997, Moscow, 1 Ostrovityaninova Str. Tel.: + 7 (910) 473-35-66

D. G Karpenko

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

117997, Moscow, 1 Ostrovityaninova Str. Tel.: + 7 (910) 473-35-66

References

  1. Simmonds M.J., Meiselman H.J., Baskurt O.K. Blood rheology and aging. J Geriatr Cardiol. 2013; 10(3): 291-301. doi: 10.3969/j. issn.1671-5411.2013.03.010.
  2. Nader E., Skinner S., Romana M. et al. Blood rheology: Key parameters, impact on blood flow, role in sickle cell disease and effects of exercise. Front Physiol. 2019; 10: 1329. doi: 10.3389/fphys.2019.01329.
  3. Ariens R.A., Coppola R., Potenza I., Mannucci P.M. The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. Blood Coagul Fibrinolysis. 1995; 6(5): 433-37. doi: 10.1097/00001721-199507000-00010.
  4. Capodanno D., Angiolillo D.J. Antithrombotic pharmacotherapy in the elderly: general issues and clinical conundrums. Curr Treat Options Cardio Vasc Med. 2012; 14(1): 57-68. doi: 10.1007/s11936-01 1-0153-6.
  5. Tajiri K., Shimizu Y. Liver physiology and liver diseases in the elderly. World J Gastroenterol. 2013; 19(46): 8459-67. doi: 10.3748/ wjg.v19.i46.8459.
  6. Pibiri M. Liver regeneration in aged mice: new insights. Aging (Albany NY). 2018; 10(8): 1801-24. doi: 10.18632/aging.101524.
  7. Wang X., Vrtiska T.J., Avula R.T. et al. Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney. Kidney Int. 2014; 85(3): 677-85. doi: 10.1038/ki.2013.359.
  8. Fang Y., Gong A.Y., Haller S.T. et al. The ageing kidney: Molecular mechanisms and clinical implications. Ageing Res Rev. 2020; 63: 101151. doi: 10.1016/j.arr.2020.101 151.
  9. Conte M., Martucci M., Sandri M. et al. The dual role of the pervasive «fattish» tissue remodeling with age. Front Endocrinol (Lausanne). 2019; 10: 114. doi: 10.3389/fendo.2019.00114.
  10. Ткачева О.Н., Воробьева Н.М., Котовская Ю.В. с соавт. Антитромботическая терапия в пожилом и старческом возрасте: согласованное мнение экспертов Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии. Кардиоваскулярная терапия и профилактика. 2021; 3: 2847. @@Tkacheva O.N., Vorobyeva N.M., KotovskayaYu.V. et al. Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2021; 3: 2847 (In Russ.). doi: http://dx.doi.org/10.15829/1728-8800-2021-2847.
  11. Laurent S. Defining vascular aging and cardiovascular risk. J Hypertens. 2012;30 Suppl: S3-8. doi: 10.1097/HJH.0b013e328353e501.
  12. Крюков А.В., Сычев Д.А., Терещенко О.В. Фармакогенетические аспекты применения новых оральных антикоагулянтов. Рациональная фармакотерапия в кардиологии. 2017; 3: 416-421. @@Kryukov A.V., Sychev D.A., Tereshchenko O.V. Pharmacogenetic aspects of new oral anticoagulants application. Ratsional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2017; 3: 416-421 (In Russ). doi: http://dx.doi.org/10.20996/1819-6446-2017-13-3-416-421.
  13. Sychev D.A., Baturina O.A., Mirzaev K.B. et al. CYP2C19*17 may increase the risk of death among patients with an acute coronary syndrome and non-valvular atrial fibrillation who receive clopidogrel and rivaroxaban. Pharmgenomics Pers Med. 2020; 13: 29-37. doi: 10.2147/PGPM.S234910.
  14. Беленков Ю.Н., Арутюнов Г.П., Барбараш О.Л. с соавт. Значение и ценность сравнительных исследований «реальной клинической практики» в современной кардиологии. Заключение совета экспертов от 18.12.2020. Кардиология. 2021; 5: 79-81. @@Belenkov Yu.N., Arutyunov G.P., Barbarash O.L. et. al. Value of comparative studies of «real clinical practice» in modern cardiology. Position paper based on the expert council discussion dated 12/18/2020. Kardiologiya = Cardiology. 2021; 5: 79-81 (In Russ.). doi: https://doi.org/10.18087/cardio.2021.5.n1646.
  15. Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19) :2369-429. doi: 10.1093/eur-heartj/ ehq278.
  16. Воробьева Н.М., Ткачева О.Н. Возможности применения ривароксабана у пожилых пациентов с фибрилляцией предсердий: данные рандомизированных исследований и реальной клинической практики. Рациональная фармакотерапия в кардиологии. 2018; 4: 575-582. @@Vorobyeva N.M., kacheva O.N. Possibilities of using rivaroxaban in elderly patients with atrial fibrillation: data from randomized studies and real clinical practice. Ratsional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2018; 4: 575-582 (In Russ.). doi: https://doi.org/10.20996/1819-6446-2018-14-4-575-582.
  17. Лядова М.В., Чуловская И.Г., Лядова А.В. Современная концепция лечения больных геронтологического профиля с переломами проксимального отдела бедренной кости (клинические, медико-правовые и социальные аспекты). Российский журнал гериатрической медицины. 2021; 2: 220-225. @@Lyadova M.V., Chulovskaya I.G., Lyadova A.V. Modern concept of treatment of gerontological patients with fractures of the proximal femur (clinical, medical, legal and social aspects). Rossiyskiy zhurnal geriatricheskoy meditsiny = Russian Journal of Geriatric Medicine. 2021; 2: 220-225 (In Russ.). doi: https://doi.org/10.37586/2686-8636-2-2021-220-225.
  18. Фомин В.В., Свистунов А.А., Напалков Д.А. с соавт. Прямые пероральные антикоагулянты у пациентов с фибрилляцией предсердий в возрасте 75 лет и старше: баланс эффективности и безопасности // Терапевтический архив. 2017; 4: 4-7. @@FominV.V., Svistunov A.A., Napalkov D.A. et. al. Direct oral anticoagulants in atrial fibrillation patients aged 75 years or older: Efficacy and safety balance. Terapevticheskiy arkhiv = Therapeutic Archive. 2017; 4: 4-7 (In Russ.). doi: https://doi.org/10.17116/terarkh20178944-7.
  19. Al-Khatib S.M., Thomas L., Wallentin L. et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013; 34(31): 2464-71. doi: 10.1093/eurheartj/eht135.
  20. Fox K.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32(19): 2387-94. doi: 10.1093/ eurheartj/ehr342.
  21. Mann K.G., Brummel K., Butenas S. What is all that thrombin for? J Thromb Haemost. 2003; 1(7): 1504-14. doi: 10.1046/j.1 538-7836.2003.00298.x.
  22. Orfeo T., Gissel M., Butenas S. et al. Anticoagulants and the propagation phase of thrombin generation. PLoS One. 2011; 6(11): e27852. doi: 10.1371/journal.pone.0027852.
  23. Patel M.R., Mahaffey K.W., Garg J. et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-91. doi: 10.1056/NEJMoa1009638.
  24. Eikelboom J.W., Connolly S.J., Bosch J. et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377(14): 1319-30. doi: 10.1056/NEJMoa1709118.
  25. Bosch J., Eikelboom J.W., Connolly S.J. et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Can J Cardiol. 2017; 33(8): 1027-35. doi: 10.1016/j. cjca.2017.06.001. www.rnmot.ru
  26. Пресс-релиз компании Байер П. Байер зарегистрировал новое показание для применения ривароксабана у пациентов с ишемической болезнью сердца или заболеванием периферических артерий на территории Европейского союза и США. Рациональная фармакотерапия в кардиологии. 2018; 5: 797. @@Press Release B. Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA. Ratsional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2018; 5: 797 (In Russ.).
  27. Руководство по практическому применению препарата Ксарелто®. Доступ: https://pharma.bayer.rU/sites/g/files/vrxlpx3916/files/2021-06/dozovaya-karta-ksarelto_1.4.pdf (дата обращения - 01.09.2021). @@Guidelines for the practical use of the drug Xarelto®. Available at: https://pharma.bayer.ru/sites/g/files/vrxlpx3916/files/2021-06/dozovaya-karta-ksarelto_1.4.pdf (date of access - 01.09.2021) (In Russ.).
  28. Duggan S.T. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery. Am J Cardiovasc Drugs. 2012; 12(1): 57-72. doi: 10.2165/1 1208470-000000000-00000.
  29. Явелов И.С. Применение ривароксабана для профилактики инсульта при неклапанной фибрилляции предсердий у больных пожилого и старческого возраста. Кардиология. 2019; 12S: 4-11. @@Yavelov I.S. Rivaroxaban in prevention of stroke in elderly patients with non-valvular atrial fibrillation. Kardiologiya = Cardiology. 2019; 12S: 4-11 (In Russ.). doi: https://doi.org/10.18087/cardio.n892.
  30. Скотников А.С., Алгиян Е.А., Сизова Ж.М. Коморбидный больной фибрилляцией предсердий в реальной клинической практике. Российский кардиологический журнал. 2020; 11: 4178. @@Skotnikov A.S., Algiyan E.A., Sizova Z.M. A patient with atrial fibrillation and comorbidities in clinical practice. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 11: 4178 (In Russ.). doi: https://doi.org/10.15829/29/1560-4071-2020-4178.
  31. Гиляревский С.Р. Совершенствованная тактика ведения больных с венозными тромбоэмболиями: роль применения ривароксабана на разных этапах терапии. Рациональная фармакотерапия в кардиологии. 2016; 3: 337-343. @@Gilyarevskiy S.R. The advanced tactics of the management of patients with venous thromboembolism: the role of rivaroxaban at various stages of treatment. Ratsional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2016; 3: 337-343 (In Russ.). doi: https://doi.org/10.20996/1819-6446-2016-12-3-337-343.
  32. Weitz J.I., Connolly S.J., Patel I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010; 104(3): 633-41. doi: 10.1160/TH10-01-0066.
  33. Turpie A.G., Lassen M.R., Eriksson B.I. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011; 105(3): 444-53. doi: 10.1160/TH10-09-0601.
  34. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467-507. doi: 10.1093/europace/euv309.
  35. Kubitza D., Becka M., Roth A., Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor. J Clin Pharmacol. 2013; 53(3): 249-55. doi: 10.1002/jcph.5.
  36. Harder S., Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013; 69(9): 1617-33. doi: 10.1007/s00228-013-1 510-z.
  37. Скрипка А.И., Когай В.В., Листратов А.И. с соавт. Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике. Терапевтический архив. 2019; 7: 111-120. @@Skripka A.I., Kogay V.V., Listratov A.I. et. al. Personalized approach for direct oral anticoagulant prescription: from theory to practice. Terapevticheskiy arkhiv = Therapeutic Archive. 2019; 91 (7): 111-120 (In Russ.). doi: 10.26442/00403660.2019.07.000045.
  38. Лесняк О.М., Фарба Л.Я., Фролова Е.В. с соавт. Меморандум о создании российского альянса «Хрупкий возраст - FFN-RUSSIA». Российский журнал гериатрической медицины. 2021; 2: 256-257. @@Lesnyak O.M., Farba L.Ya., Frolova E.V. et al. A memorandum on the creation of the Russian Alliance «Fragile age - FFN-RUSSIA». Rossiyskiy zhurnal geriatricheskoy meditsiny = Russian Journal of Geriatric Medicine. 2021; 2: 256-257 (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies